Evidence map›Paper›PMID 25888331›Full record

ArticleBMC urology2015

A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.

Laimonis Kavalieris, Paul J O'Sullivan, James M Suttie, Brent K Pownall, Peter J Gilling, Christophe Chemasle, David G Darling

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05349812 (An Observational Study of Cxbladder Performance for Detection or Rule-out of Upper Tract Urothelial Cancer), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05349812 withdrawnnot on this mapstarted 2022, after this paper: background citation

An Observational Study of Cxbladder Performance for Detection or Rule-out of Upper Tract Urothelial Cancer

TypeobservationalSponsorPacific Edge LimitedRan2022 to 2023Enrolled0ConditionsUpper Tract Urinary Carcinoma
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Analytical Validation of the CxbladderDiagnostics (Basel, Switzerland) · 2025
    Article
  11. Article
  12. Review
  13. Analytical Validation of CxbladderDiagnostics (Basel, Switzerland) · 2024
    Article
  14. Do All Low Risk Microhematuria Patients Require Cystoscopy?Bladder cancer (Amsterdam, Netherlands) · 2024
    Article
  15. Urinary Analysis ofThe Journal of urology · 2023
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Can urinary biomarkers replace cystoscopy?World journal of urology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Laimonis KavalierisPacific Edge Ltd, Dunedin, New Zealand. lkavalieris@pacificedge.co.nz.
Paul J O'SullivanPacific Edge Ltd, Dunedin, New Zealand. paul.osullivan@pacificedge.co.nz.
James M SuttiePacific Edge Ltd, Dunedin, New Zealand. jimmy.suttie@pelnz.com.
Brent K PownallPacific Edge Diagnostics Ltd, Dunedin, New Zealand. brent.pownall@pacificedgedx.com.
Peter J GillingTauranga Urology Research, Tauranga, New Zealand. peter@promed.co.nz.
Christophe ChemasleDepartment of Urology, Palmerston North Hospital, Palmerston North, New Zealand. christophe.chemasle@midcentraldhb.govt.nz.
David G DarlingPacific Edge Ltd, Dunedin, New Zealand. dave.darling@pelnz.com.
Palmerston North Hospital · NZTauranga Hospital · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHematuria can be symptomatic of urothelial carcinoma (UC) and ruling out patients with benign causes during primary evaluation is challenging. Patients with hematuria undergoing urological work-ups place significant clinical and financial burdens on healthcare systems. Current clinical evaluation involves processes that individually lack the sensitivity for accurate determination of UC. Algorithms and nomograms combining genotypic and phenotypic variables have largely focused on cancer detection and failed to improve performance. This study aimed to develop and validate a model incorporating both genotypic and phenotypic variables with high sensitivity and a high negative predictive value (NPV) combined to triage out patients with hematuria who have a low probability of having UC and may not require urological work-up.

methodsExpression of IGFBP5, HOXA13, MDK, CDK1 and CXCR2 genes in a voided urine sample (genotypic) and age, gender, frequency of macrohematuria and smoking history (phenotypic) data were collected from 587 patients with macrohematuria. Logistic regression was used to develop predictive models for UC. A combined genotypic-phenotypic model (G + P INDEX) was compared with genotypic (G INDEX) and phenotypic (P INDEX) models. Area under receiver operating characteristic curves (AUC) defined the performance of each INDEX: high sensitivity, NPV >0.97 and a high test-negative rate was considered optimal for triaging out patients. The robustness of the G + P INDEX was tested in 40 microhematuria patients without UC.

resultsThe G + P INDEX offered a bias-corrected AUC of 0.86 compared with 0.61 and 0.83, for the P and G INDEXs respectively. When the test-negative rate was 0.4, the G + P INDEX (sensitivity = 0.95; NPV = 0.98) offered improved performance compared with the G INDEX (sensitivity = 0.86; NPV = 0.96). 80% of patients with microhematuria who did not have UC were correctly triaged out using the G + P INDEX, therefore not requiring a full urological work-up.

conclusionThe adoption of G + P INDEX enables a significant change in clinical utility. G + P INDEX can be used to segregate hematuria patients with a low probability of UC with a high degree of confidence in the primary evaluation. Triaging out low-probability patients early significantly reduces the need for expensive and invasive work-ups, thereby lowering diagnosis-related adverse events and costs.

Indexed as

AdultAgedAged, 80 and overAustraliaBiomarkers, TumorCausalityComorbidityFemaleHematuriaHumansIncidenceMaleMiddle AgedNeoplasm ProteinsNew ZealandReproducibility of ResultsBiomarkers, TumorNeoplasm Proteins

Identifiers

PMID25888331
PMCPMC4391477
OpenAlexW2155584012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.